FINWIRES · TerminalLIVE
FINWIRES

$ALT

7 stories mentioning ALTUpdated just now

Every FINWIRES story that references ALT, newest first.

Wire

Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH

Altimmune (ALT) said Monday it has started enrolling patients in the phase 3 PERFORMA trial evaluating pemvidutide in patients with metabolic dysfunction-associated steatohepatitis, or MASH.The global, randomized, double-blind, placebo-controlled study aims to evaluate the efficacy, safety, and clinical outcomes of pemvidutide in MASH patients with moderate-to-advanced fibrosis, the company said.Altimmune said that the trial follows findings from the phase 2b IMPACT trial and incorporates feedback from the US Food and Drug Administration and European regulatory agencies.The company said it expects to publish a 52-week data readout from the trial in 2029.Shares of the company were up 1.4% in Monday's premarket activity.

$ALT
Wire

Altimmune's Investigational Alcohol Use Disorder Drug Meets Primary Endpoint in Phase 2 Study

Altimmune's (ALT) investigational drug Pemvidutide met its primary and several secondary endpoints in a phase 2 study for treatment of alcohol use disorder, the company said Tuesday.A 2.4 mg dose yielded a "statistically significant and clinically meaningful" reduction in heavy drinking days versus placebo, the primary endpoint of the approximately 100-patient study, the company said.The company also met secondary endpoints including a two-level reduction in World Health Organization Risk Drinking Levels and achieving zero heavy-drinking days versus placebo, the company said.The drug also showed generally favorable tolerability, the company said.Based on the data, Altimmune plans to request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration to discuss pemvidutide's path forward in alcohol use disorder, the company said.Shares of the company were up more than 11% in recent premarket trading.

$ALT
Research

Leerink Partners Initiates Altimmune at Outperform With $10 Price Target

Altimmune (ALT) has an average rating of overweight and mean price target of $16.06, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$ALT
Wire

Altimmune Says Pemvidutide Data Show Metabolic Improvements in MASH Patients

Altimmune (ALT) said Thursday new 48-week data from the Impact phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly lowered elevated lipids while improving multiple cardio-metabolic risk factors in patients with metabolic dysfunction-associated steatohepatitis, or MASH.The findings demonstrated reductions in triglycerides and total cholesterol, along with improvements in weight, waist circumference and blood pressure, highlighting pemvidutide's efficacy on key drivers of MASH, the company said.The data was presented for the first time at the European Association for the Study of the Liver Congress 2026 in Barcelona, Spain.Results also showed that the safety profile of pemvidutide was maintained at 48 weeks and the tolerability profile was generally favorable without dose titration, the company added.Shares of Altimmune rose more than 3% in Thursday trading.Price: $3.07, Change: $+0.09, Percent Change: +3.15%

$ALT
Wire

Altimmune's Phase 2b Trial Data for Pemvidutide Demonstrates Improvements in Liver Disease

Altimmune (ALT) said Wednesday that data from the phase 2b trial of pemvidutide to treat liver disease demonstrated improvements across non-invasive tests of metabolic dysfunction-associated steatohepatitis activity and fibrosis at 24 weeks compared with placebo.AI-based pathology showed that pemvidutide treatment led to considerable reductions in fibrosis values compared with placebo, according to a statement.The company will start patient enrollment for its phase 3 trial of the drug in H2 based on the latest phase 2b results, according to the company.Price: $2.99, Change: $+0.06, Percent Change: +2.05%

$ALT
Research

Goldman Sachs Upgrades Altimmune to Neutral From Sell, Adjusts Price Target to $2.50 From $1

Altimmune (ALT) has an average rating of buy and mean price target of $18.15, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$ALT
Wire

Altimmune Prices $225 Million Public Offering; Shares Fall Pre-Bell

Altimmune (ALT) said Wednesday it priced its underwritten public offering, consisting of about 64.3 million common shares and accompanying warrants to buy an about 64.3 million common shares and pre-funded warrants to buy up to about 10.8 million common shares and accompanying warrants to buy about 10.8 million common shares.The combined offering price of each common share and accompanying warrant is $3, while the combined offering price of each pre-funded warrant and accompanying common stock warrant is $2.999.The offering is set to close around Friday.Gross proceeds from the offering, set to close around Friday, are estimated to be about $225 million.Altimmune said it plans to use the net proceeds to fund its upcoming phase 3 trial in metabolic dysfunction-associated steatohepatitis, as well as for working capital and general corporate purposes.The company's shares were down over 13% during Thursday premarket activity.Price: $3.00, Change: $-0.47, Percent Change: -13.45%

$ALT

Track with the FINWIRES app suite

FolioX
FolioX
Track ALT in your portfolio
WheelAI
WheelAI
Analyze ALT options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ALT